The drug company's second IPO will see three of its heavyweight products go on the market

"Pharmaceutical Network Enterprise News" recently reported that Synth Pharmaceuticals on October 27 officially landed on the main board of the Hong Kong Stock Exchange, the opening price of 11 Hong Kong dollars / share, closed at noon, the market value of more than 28 billion Hong Kong dollars.
is worth mentioning, this is also the first sound pharmaceutical industry to break through the IPO for the second time.
20, 2007, Synsheng Pharmaceuticals was listed on the NYSE, becoming the first Chinese biopharmaceutical company to list on the NYSE.
set a record for the largest IPO of a pharmaceutical company in Asia at the time with a $226m capital raising and a market capitalisation of more than $1bn.
was subsequently privatised in December 2013 and de-stocked from the U.S. stock market in 2014.
financial data show that in 2017-2019, Synsheng Pharmaceuticals achieved sales revenue of 3.868 billion yuan, 4.514 billion yuan and 5.037 billion yuan, respectively, with net profit of 350 million yuan, 734 million yuan and 1.004 billion yuan, with a compound annual growth rate of 69.2%.
addition, in 2017-2019, the gross margin of Synth Pharmaceuticals was 84.8%, 82.9% and 82.4%, respectively.
as of June 30, 2020, gross margin was 79.8%, compared with 82.3% for the same period in 2019.
recent years, the company has continued to increase research and development.
2017-2019, the company's research and development investment as a percentage of sales revenue of 5.5%, 9.9% and 14.2%, respectively, to achieve year-on-year growth trend.
As of June 30, 2020, Synth Pharmaceuticals has more than 2,800 sales and marketing staff in 31 provinces, municipalities and autonomous regions of China, covering approximately 2,100 level III hospitals, approximately 17,000 other hospitals and medical institutions, and more than 200 large national or regional pharmacies.
three heavyweight products will be launched in the first sound pharmaceutical industry mainly focused on the tumor, central nervous system and autoimmune diseases in the three major diseases of drug research and development, production and commercialization, and formed a rich product pipeline.
according to Frost Sullivan, these three therapeutic areas together accounted for 24.7% of China's drug market in 2019 in terms of drug sales revenue.
In terms of specific product pipelines, in the field of cancer diseases, Synthesic Pharmaceuticals has 5 listed products such as Endo, Jebshu, Je suis, and Chinese fluorine, in the field of central nervous system diseases, it has 3 listed products, including the necessary existing products, and in the field of autoimmune diseases, it has 4 listed products with Aedes ades ades aeon and Intra-Taiqing as the core.
addition, in the field of cardiovascular disease, Sonic Pharmaceuticals has a number of generic drugs, including Shuftan and other 3 products on the market, in the field of anti-infective diseases, there are 15 products on the market.
it's worth noting that many of its drugs are already covered by the National Health Insurance.
as of June 30, 2020, more than 30 products in the company's existing portfolio have been included in the National Health Insurance Drug Catalog, and more than 10 products have been entered into more than 40 clinical practice guidelines and pathways. According to the
prospecto, the company currently has nearly 50 innovative pharmaceutical products at various stages of development, including small molecule drugs, large molecule drugs and CAR-T cell therapy, of which more than 10 are in the clinical stage of research and innovation products, have submitted new drug declarations or have been approved.
it is understood that the company expects to have three heavy-duty products on the market in 2020-2021, namely, a class of innovative drug Idara feng rightol injection with a thick solution (Idalafon compound preparation), PD-L1 inhibitor KN035 (Envafolimab) and imported innovative drug Obraciaren (Abrasip injection).
, the stroke treatment drug Idalafon compound preparation is expected to become the world's first approved new stroke drug for sale in nearly five years.
PD-L1 mono-resistant variety KN035 is also expected to become the world's first under-skin injection of PD-L1 monoantigen.